User profiles for Karen King
Karen E. KingAssociate Professor, Pathology and Oncology, Johns Hopkins University Verified email at jhmi.edu Cited by 8635 |
[HTML][HTML] The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis
…, MA Rodriguez-Bigas, SL Jester, KL King… - … England Journal of …, 2000 - Mass Medical Soc
Background Patients with familial adenomatous polyposis have a nearly 100 percent risk of
colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal …
colorectal cancer. In this disease, the chemopreventive effects of nonsteroidal …
[BOOK][B] What is gnosticism?
KL King - 2003 - books.google.com
… To do so, Karen King says, we must first disentangle modern historiography from the …
King shows how historians have been misled by ancient Christian polemicists who attacked …
King shows how historians have been misled by ancient Christian polemicists who attacked …
The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs
J Zhang, F Visser, KM King, SA Baldwin… - Cancer and Metastasis …, 2007 - Springer
Nucleoside analogs are important components of treatment regimens for various malignancies.
Nucleoside-specific membrane transporters mediate plasma membrane permeation of …
Nucleoside-specific membrane transporters mediate plasma membrane permeation of …
[HTML][HTML] C4d and C3d staining in biopsies of ABO-and HLA-incompatible renal allografts: correlation with histologic findings
Biopsies of ABO-incompatible and positive crossmatch (HLA-incompatible) renal allografts
were retrospectively examined to compare results of C4d and C3d staining, and the …
were retrospectively examined to compare results of C4d and C3d staining, and the …
Prevention of allergic transfusion reactions to platelets and red blood cells through plasma reduction
BACKGROUND: The incidence of allergic transfusion reactions (ATRs) ranges from 1% to 3%
of all transfusions, and they are difficult to prevent. This study evaluated whether removing …
of all transfusions, and they are difficult to prevent. This study evaluated whether removing …
Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27
…, VG Vogel, SR Dakhil, D Tamkus, KM King… - Journal of Clinical …, 2008 - ascopubs.org
Purpose National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18 was
designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) …
designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) …
Genes mirror geography within Europe
Understanding the genetic structure of human populations is of fundamental interest to
medical, forensic and anthropological sciences. Advances in high-throughput genotyping …
medical, forensic and anthropological sciences. Advances in high-throughput genotyping …
Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
…, J Huber, Y Li, A Santiago, W O'Connor, K King… - Cancer research, 1999 - AACR
Tumor angiogenesis is mediated by tumor-secreted angiogenic growth factors that interact
with their surface receptors expressed on endothelial cells. Vascular endothelial growth factor …
with their surface receptors expressed on endothelial cells. Vascular endothelial growth factor …
[HTML][HTML] Desensitization in HLA-incompatible kidney recipients and survival
RA Montgomery, BE Lonze, KE King… - … England Journal of …, 2011 - Mass Medical Soc
Background More than 20,000 candidates for kidney transplantation in the United States
are sensitized to HLA and may have a prolonged wait for a transplant, with a reduced …
are sensitized to HLA and may have a prolonged wait for a transplant, with a reduced …
Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully …
…, AA Zachary, LC Racusen, MS Leffell, KE King… - …, 2000 - journals.lww.com
Background. Hyperacute rejection (HAR) and acute humoral rejection (AHR) remain recalcitrant
conditions without effective treatments, and usually result in graft loss. Plasmapheresis (…
conditions without effective treatments, and usually result in graft loss. Plasmapheresis (…